Pharmaceutical News and Articles

Arrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran

PASADENA, Calif. (BUSINESS WIRE) Nov. 18, 2024 Arrowhead Pharmaceuticals, Inc. (NASDAQ ARWR) today announced new results from the Phase 3 PALISADE study and the

Muvalaplin lowered lipoprotein(a) levels in adults with high risk for cardiovascular events by up to 85% at highest tested dose

INDIANAPOLIS, Nov. 18, 2024. Eli Lilly and Company today announced positive Phase 2 results for muvalaplin, an investigational once-daily, orally administered s

Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months

PALO ALTO, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) BridgeBio Pharma, Inc. (Nasdaq BBIO) ( BridgeBio or the Company ), a new type of biopharmaceutical company foc

Diabetes Meds Metformin, GLP-1s Can Also Curb Asthma

Drugs already taken by millions of diabetes patients appear to also help slash asthma attacks by up to 70 , new British research shows. The two drugs are metfor

Tirzepatide Yields Sustained Weight Reduction in Obesity, Prediabetes

For patients with obesity and prediabetes, three years of tirzepatide yields substantial and sustained weight reduction and a reduced risk for progression to ty

AHA: AI Analysis of Images, Videos Can ID Early Hypertension, Diabetes

Machine learning analysis of photo and video data demonstrates a promising way to noninvasively detect early hypertension and diabetes, according to a study pre

AHA: Rising Outdoor Temperatures Tied to Higher Risk for Atrial Fibrillation

There is a dose-response relationship between rising outdoor temperatures and increased atrial fibrillation (AF) events, according to a study presented at the A

ChemoRT Then Immunochemotherapy Then Surgery Promising in Unresectable Esophageal Cancer

For patients with unresectable locally advanced esophageal squamous cell carcinoma (ESCC), chemoradiotherapy (CRT) followed by immunochemotherapy (iCT) and then

Beta Blockers May Cause Depressive Symptoms

Beta-blocker treatment can lead to a modest increase in depressive symptoms among patients who have myocardial infarction with preserved left ventricular ejecti

Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease